Eurofarma Ventures

Eurofarma Ventures is the corporate venture arm of Eurofarma, one of Latin America’s largest pharmaceutical manufacturers, headquartered in Sao Paulo and deploying $1M-$5M cheques at Seed, Series A, and Series B into innovative drug delivery, biotech, and digital health platforms. The firm operates as a strategic CVC with explicit interest in technologies that can integrate with Eurofarma’s R&D, manufacturing, or commercial pipeline across Brazil and broader LatAm. For founders, Eurofarma Ventures is best positioned as a strategic pharma-affiliated investor for biotech, drug delivery, and clinically-anchored digital health founders with a credible thesis on pharma collaboration. The right founder profile is a Brazilian or LatAm-deploying operator building a defensible biotech, drug delivery technology, clinical trial software, or pharma-adjacent digital health platform with technical depth and a clear regulatory pathway through ANVISA and broader LatAm health agencies. Founders running consumer wellness, asset-heavy clinic chains, or pure SaaS plays without pharma intersection are a poor fit. The cleanest entry path is via Eurofarma’s R&D or business development teams, a portfolio CEO, or warm introductions from biotech and pharma-focused global funds. In the pitch, lead with scientific defensibility, IP strategy, regulatory positioning, and a concrete plan for Eurofarma collaboration that goes beyond generic strategic synergy claims. Caveats: as a CVC, Eurofarma weighs strategic alignment alongside financial return, and term sheets may include rights of first refusal, licensing options, or distribution exclusivity worth negotiating carefully. AI focus is not stated, so AI-heavy founders should expect commercial rather than technical diligence. Decision cadence is institutional given the corporate parent. Confirm reserves and pacing explicitly during initial diligence.